dostęp otwarty

Tom 8, Nr 2 (2017)
PRACE POGLĄDOWE
Opublikowany online: 2017-09-06
Pobierz cytowanie

Rozpoznawanie i leczenie chorych na chłoniaka rozlanego z dużych komórek B

Krzysztof Warzocha, Bartosz Puła
DOI: 10.5603/Hem.2017.0015
·
Hematologia 2017;8(2):113-131.

dostęp otwarty

Tom 8, Nr 2 (2017)
PRACE POGLĄDOWE
Opublikowany online: 2017-09-06

Streszczenie

Chłoniak rozlany z dużych komórek B (DLBCL) jest najczęściej występującym typem chłoniaka u chorych w różnych grupach wiekowych oraz charakteryzującym się agresywnym przebiegiem klinicznym. Poza lokalizacjami węzłowymi DLBCL może również dotyczyć innych narządów, prowadząc do zróżnicowanych manifestacji klinicznych, dlatego stanowi on istotny element w diagnostyce różnicowej wielu chorób. Około 60% chorych, mimo zaawansowania choroby, może zostać wyleczonych za pomocą immunochemioterapii rytuksymabem oraz lekami cytotoksycznymi. Jednak rokowanie w przypadkach nawrotowych i opornych jest niekorzystne. Ostatnie postępy w dziedzinie biologii molekularnej pozwoliły na lepsze zdefiniowanie tej heterogennej grupy chłoniaków, co, być może, przyczyni się do indywidualizacji leczenia oraz poprawy rokowania chorych. W niniejszej publikacji przedstawiono zalecenia odnośnie do diagnostyki, leczenia oraz monitorowania chorych na DLBCL.

Streszczenie

Chłoniak rozlany z dużych komórek B (DLBCL) jest najczęściej występującym typem chłoniaka u chorych w różnych grupach wiekowych oraz charakteryzującym się agresywnym przebiegiem klinicznym. Poza lokalizacjami węzłowymi DLBCL może również dotyczyć innych narządów, prowadząc do zróżnicowanych manifestacji klinicznych, dlatego stanowi on istotny element w diagnostyce różnicowej wielu chorób. Około 60% chorych, mimo zaawansowania choroby, może zostać wyleczonych za pomocą immunochemioterapii rytuksymabem oraz lekami cytotoksycznymi. Jednak rokowanie w przypadkach nawrotowych i opornych jest niekorzystne. Ostatnie postępy w dziedzinie biologii molekularnej pozwoliły na lepsze zdefiniowanie tej heterogennej grupy chłoniaków, co, być może, przyczyni się do indywidualizacji leczenia oraz poprawy rokowania chorych. W niniejszej publikacji przedstawiono zalecenia odnośnie do diagnostyki, leczenia oraz monitorowania chorych na DLBCL.

Pobierz cytowanie

Słowa kluczowe

chłoniak rozlany z dużych komórek B, diagnostyka, immunochemioterapia, rytuksymab, leczenie

Informacje o artykule
Tytuł

Rozpoznawanie i leczenie chorych na chłoniaka rozlanego z dużych komórek B

Czasopismo

Hematologia

Numer

Tom 8, Nr 2 (2017)

Strony

113-131

Data publikacji on-line

2017-09-06

DOI

10.5603/Hem.2017.0015

Rekord bibliograficzny

Hematologia 2017;8(2):113-131.

Słowa kluczowe

chłoniak rozlany z dużych komórek B
diagnostyka
immunochemioterapia
rytuksymab
leczenie

Autorzy

Krzysztof Warzocha
Bartosz Puła

Referencje (108)
  1. Juszczyński P. Struktura genetyczna chłoniaków rozlanych z dużych komórek B: od mikromacierzy DNA do celowanej terapii. Hematologia. 2010; 1(1): 15–28.
  2. Swerdlow SH, Campo E, Piler SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20): 2375–2390.
  3. Swerdlow SH. WHO classification of tumours of haematopoietic and lymphoid tissues. Fourth edition. IARC Press, Lyon 2008.
  4. Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene. 2004; 23(38): 6524–6534.
  5. Cerhan JR, Slager SL. Familial predisposition and genetic risk factors for lymphoma. Blood. 2015; 126(20): 2265–2273.
  6. Morton LM, Slager SL, Cerhan JR, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014; 2014(48): 130–144.
  7. Oyama T, Yamamoto K, Asano N, et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res. 2007; 13(17): 5124–5132.
  8. Shimoyama Y, Asano N, Kojima M, et al. Age-related EBV-associated B-cell lymphoproliferative disorders: diagnostic approach to a newly recognized clinicopathological entity. Pathol Int. 2009; 59(12): 835–843.
  9. Melenotte C, Million M, Audoly G, et al. B-cell non-Hodgkin lymphoma linked to Coxiella burnetii. Blood. 2016; 127(1): 113–121.
  10. Abruzzo L, Rosales C, Medeiros L, et al. Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol. 2002; 26(5): 630–636.
  11. Sohani AR, Ferry JA, Chang PS, et al. Epstein-Barr virus-positive diffuse large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic leukemia. J Clin Oncol. 2010; 28(5): e69–e72.
  12. Jamroziak K, Tadmor T, Robak T, et al. Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy. Leuk Lymphoma. 2015; 56(7): 1949–1958.
  13. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001; 412(6844): 341–346.
  14. Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol. 2008; 8(1): 22–33.
  15. Ye BH, Lista F, Lo Coco F, et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science. 1993; 262(5134): 747–750.
  16. Offit K, Louie DC, Parsa NZ, et al. BCL6 gene rearrangement and other cytogenetic abnormalities in diffuse large cell lymphoma. Leuk Lymphoma. 1995; 20(1-2): 85–89.
  17. Offit K, Lo Coco F, Louie DC, et al. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med. 1994; 331(2): 74–80.
  18. Volpe G, Vitolo U, Carbone A, et al. Molecular heterogeneity of B-lineage diffuse large cell lymphoma. Genes Chromosomes Cancer. 1996; 16(1): 21–30, doi: 10.1002/(SICI)1098-2264(199605)16:1<21::AID-GCC3>3.0.CO;2-5.
  19. Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014; 11(1): 12–23.
  20. Davis RE, Ngo VuN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010; 463(7277): 88–92.
  21. Ueda C, Nishikori M, Kitawaki T, et al. Coexistent rearrangements of c-MYC, BCL2, and BCL6 genes in a diffuse large B-cell lymphoma. Int J Hematol. 2004; 79(1): 52–54.
  22. Yunis JJ, Mayer MG, Arnesen MA, et al. bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med. 1989; 320(16): 1047–1054.
  23. Rosenthal A, Younes A. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma. Blood Rev. 2017; 31(2): 37–42.
  24. Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013; 121(20): 4021–31; quiz 4250.
  25. Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014; 166(6): 891–901.
  26. Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014; 124(15): 2354–2361.
  27. Sesques P, Johnson NA. Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. Blood. 2017; 129(3): 280–288.
  28. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769): 503–511.
  29. Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA. 2008; 105(36): 13520–13525.
  30. Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA. 2003; 100(17): 9991–9996.
  31. Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009; 459(7247): 717–721.
  32. Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001; 194(12): 1861–1874.
  33. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003; 198(6): 851–862.
  34. Alcoceba M, Sebastián E, Marín L, et al. HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma. Blood. 2013; 122(8): 1448–1454.
  35. Cerhan JR, Berndt SI, Vijai J, et al. Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nat Genet. 2014; 46(11): 1233–1238.
  36. Cheson BD, Fisher RI, Barrington SF, et al. Alliance, Australasian Leukaemia and Lymphoma Group, Eastern Cooperative Oncology Group, European Mantle Cell Lymphoma Consortium, Italian Lymphoma Foundation, European Organisation for Research, Treatment of Cancer/Dutch Hemato-Oncology Group, Grupo Español de Médula Ósea, German High-Grade Lymphoma Study Group, German Hodgkin's Study Group, Japanese Lymphorra Study Group, Lymphoma Study Association, NCIC Clinical Trials Group, Nordic Lymphoma Study Group, Southwest Oncology Group, United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27): 3059–3068.
  37. Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2011; 29(11): 1452–1457.
  38. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014; 32(27): 3048–3058.
  39. Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26(Suppl 5): v116–v125.
  40. Khan AB, Barrington SF, Mikhaeel NG, et al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood. 2013; 122(1): 61–67.
  41. Giebel S. Profilaktyka i leczenie zajęcia ośrodkowego układu nerwowego w nowotworach układu chłonnego. Hematologia. 2010; 1(4): 352–358.
  42. Prochorec-Sobieszek M. Pułapki w diagnostyce chłoniaków z komórek B. Hematologia. 2010; 1(4): 271–279.
  43. Chaganti S, Illidge T, Barrington S, et al. British Committee for Standards in Haematology. Guidelines for the management of diffuse large B-cell lymphoma. Br J Haematol. 2016; 174(1): 43–56.
  44. Cheng CL, O'Connor S. T cell-rich lymphoid infiltrates with large B cells: a review of key entities and diagnostic approach. J Clin Pathol. 2017; 70(3): 187–201.
  45. Choi WWL, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009; 15(17): 5494–5502.
  46. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103(1): 275–282.
  47. Abramson JS. T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management. Oncologist. 2006; 11(4): 384–392.
  48. Booman M, Szuhai K, Rosenwald A, et al. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways. J Pathol. 2008; 216(2): 209–217.
  49. Booman M, Douwes J, Glas AM, et al. Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-cell lymphoma. Clin Cancer Res. 2006; 12(9): 2698–2705.
  50. Jordanova ES, Riemersma SA, Philippo K, et al. Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system. Genes Chromosomes Cancer. 2002; 35(1): 38–48.
  51. Wilcox RA. Cutaneous B-cell lymphomas: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016; 91(10): 1052–1055.
  52. Castillo JJ, Beltran BE, Miranda RN, et al. EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016; 91(5): 529–537.
  53. Pelosi E, Penna D, Douroukas A, et al. Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study. Q J Nucl Med Mol Imaging. 2011; 55(4): 469–475.
  54. International non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329(14): 987–994.
  55. Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28(14): 2373–2380.
  56. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007; 109(5): 1857–1861.
  57. Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2013; 123(6): 837–842.
  58. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968; 16(5): 622–626.
  59. Miller MD, Paradis C, Houck P, et al. Rating chronic medical illness burden in geropsychiatric practice and research: Application of the Cumulative Illness Rating Scale. Psychiatry Research. 1992; 41(3): 237–248.
  60. Diem S, Ess S, Cerny Th, et al. Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis. Eur J Intern Med. 2014; 25(6): 577–582.
  61. McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976; 38(4): 1484–1493, doi: 10.1002/1097-0142(197610)38:4<1484::aid-cncr2820380407>3.0.co;2-i.
  62. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993; 328(14): 1002–1006.
  63. Pfreundschuh M, Trümper L, Kloess M. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004; 104(3): 634–641.
  64. Pfreundschuh M, Trümper L, Kloess M, et al. German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004; 104(3): 626–633.
  65. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(4): 235–242.
  66. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005; 23(18): 4117–4126.
  67. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010; 116(12): 2040–2045.
  68. Pfreundschuh M, Trümper L, Österborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7(5): 379–391.
  69. Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol. 2013; 14(6): 525–533.
  70. Cunningham D, Hawkes E, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. The Lancet. 2013; 381(9880): 1817–1826.
  71. Récher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011; 378(9806): 1858–1867.
  72. Greb A, Bohlius J, Schiefer D, et al. High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults. Cochrane Database Syst Rev. 2008(1): CD004024.
  73. Epperla N, Hamadani M. Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: current controversies and advances. Hematol Oncol Stem Cell Ther. 2017 [Epub ahead of print].
  74. Lai C, Roschewski M, Melani C, et al. MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R. Leuk Lymphoma. 2017 [Epub ahead of print].
  75. Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008; 26(16): 2717–2724.
  76. Wilson WH, Jung SH, Porcu P, et al. Cancer Leukemia Group B. A cancer and leukemia group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012; 97(5): 758–765.
  77. Vellenga E, van Putten WLJ, van 't Veer MB, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood. 2008; 111(2): 537–543.
  78. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28(27): 4184–4190.
  79. Gisselbrecht C, Schmitz N, Mounier N, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol. 2012; 30(36): 4462–4469.
  80. Thieblemont C, Briere J, Mounier N, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol. 2011; 29(31): 4079–4087.
  81. Horwitz SM, Negrin RS, Blume KG, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood. 2004; 103(3): 777–783.
  82. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004; 103(10): 3684–3688.
  83. Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014; 32(31): 3490–3496.
  84. Fruchart C, Tilly H, Morschhauser F, et al. Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2014; 20(12): 1905–1911.
  85. Briones J, Novelli S, Garcia-Marco JA, et al. Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica. 2014; 99(3): 505–510.
  86. Shimoni A, Avivi I, Rowe JM, et al. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer. 2012; 118(19): 4706–4714.
  87. van Kampen RJ, Canals C, Schouten HC, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol. 2011; 29(10): 1342–1348.
  88. Mounier N, El Gnaoui T, Tilly H, et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica. 2013; 98(11): 1726–1731.
  89. Pettengell R, Coiffier B, Narayanan G, et al. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2012; 13(7): 696–706.
  90. Dunleavy K, Roschewski M, Wilson WH. Precision treatment of distinct molecular subtypes of diffuse large B-cell lymphoma: ascribing treatment based on the molecular phenotype. Clin Cancer Res. 2014; 20(20): 5182–5193.
  91. Bacher U, Klyuchnikov E, Le-Rademacher J, et al. Lymphoma Working Committee of the CIBMTR. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood. 2012; 120(20): 4256–4262.
  92. Martelli M, Ferreri AJM, Agostinelli C, et al. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013; 87(2): 146–171.
  93. Chiappella A, Castellino A, Nicolosi M, et al. Diffuse large B-cell lymphoma in the elderly: standard treatment and new perspectives. Expert Rev Hematol. 2017; 10(4): 289–297.
  94. Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011; 12(5): 460–468.
  95. Kridel R, Dietrich PY. Prevention of CNS relapse in diffuse large B-cell lymphoma. Lancet Oncol. 2011; 12(13): 1258–1266.
  96. Dzietczenia J, Wróbel T. Pierwotny chłoniak ośrodkowego układu nerwowego. Hematologia. 2013; 4(1): 7–14.
  97. Vitolo U, Seymour JF, Martelli M, et al. ESMO Guidelines Committee. Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(Suppl 5): v91–v102.
  98. Kalinka-Warzocha E. Leczenie chorych z chłoniakami i współistniejącym zakażeniem HCV, HBV lub HIV. Hematologia. 2010; 1(24): 296–305.
  99. Turner NC, Dusheiko G, Jones A. Hepatitis C and B-cell lymphoma. Ann Oncol. 2003; 14(9): 1341–1345.
  100. Frickhofen N, Wiesneth M, Jainta C, et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood. 1994; 83(7): 1998–2004.
  101. Seto WK, Chan TSY, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol. 2014; 32(33): 3736–3743.
  102. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology. 2007; 45(2): 507–539.
  103. Lok ASF, Ward JW, Perrillo RP, et al. Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. Ann Intern Med. 2012; 156(10): 743–745.
  104. Sarker D, Thirlwell C, Nelson M, et al. Leptomeningeal disease in AIDS-related non-Hodgkin's lymphoma. AIDS. 2003; 17(6): 861–865.
  105. Desai J, Mitnick R, Henry D, et al. Patterns of central nervous system recurrence in patients with systemic human immunodeficiency virus-associated non-Hodgkin lymphoma. Cancer. 1999; 86(9): 1840–1847, doi: 10.1002/(sici)1097-0142(19991101)86:9<1840::aid-cncr28>3.0.co;2-c.
  106. Coutinho R, Pria AD, Gandhi S, et al. HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era. AIDS. 2014; 28(5): 689–697.
  107. Boué F, Gabarre J, Gisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol. 2006; 24(25): 4123–4128.
  108. Diez-Martin JL, Balsalobre P, Re A, et al. Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood. 2009; 113(23): 6011–6014.

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl